Compare SIMO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | MYGN |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 481.6M |
| IPO Year | 2005 | 1996 |
| Metric | SIMO | MYGN |
|---|---|---|
| Price | $125.80 | $4.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $114.38 | $7.64 |
| AVG Volume (30 Days) | 427.1K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $46.00 | $7.19 |
| Revenue Next Year | $13.84 | $5.64 |
| P/E Ratio | $36.09 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $37.21 | $3.76 |
| 52 Week High | $146.85 | $10.30 |
| Indicator | SIMO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 43.84 |
| Support Level | $84.79 | $3.93 |
| Resistance Level | $145.77 | $5.63 |
| Average True Range (ATR) | 5.66 | 0.35 |
| MACD | -0.54 | 0.01 |
| Stochastic Oscillator | 64.06 | 30.77 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.